Moses Makunje
Financieel Directeur/CFO bij NUVATION BIO INC.
Vermogen: 27 803 $ op 30-04-2024
Actieve functies van Moses Makunje
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| NUVATION BIO INC. | Comptroller/Controller/Auditor | 27-11-2023 | - |
| Financieel Directeur/CFO | 27-11-2023 | - | |
| Corporate Officer/Principal | 01-07-2020 | 27-11-2023 |
Loopbaan van Moses Makunje
Eerdere bekende functies van Moses Makunje
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01-03-2019 | 01-07-2020 |
Statistieken
Internationaal
| Verenigde Staten | 3 |
Operationeel
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NUVATION BIO INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
- Beurs
- Insiders
- Moses Makunje
- Ervaring
